Anavex’s blarcasemine nets win in Phase IIb/III Alzheimer’s extension study
Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.
01 August 2025
01 August 2025
Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.